The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Anticancer Drugs
; 33(7): 663-670, 2022 08 01.
Article
en En
| MEDLINE
| ID: mdl-35703239
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Carcinoma Intraductal no Infiltrante
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Anticancer Drugs
Asunto de la revista:
ANTINEOPLASICOS
Año:
2022
Tipo del documento:
Article